Navigation Links
Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM)

AMSTERDAM, November 30 /PRNewswire/ -- Biopharmaceutical company Kiadis Pharma announces today that the first patients have been enrolled in its multinational registration clinical trial with ATIR(TM). The study is designed to show reduction in transplant related mortality (TRM) after one year following an allogeneic stem cell transplantation with a mismatched (haplo-identical) donor in blood cancer patients eligible for an allogeneic stem cell transplantation but without having a matched donor available.

The study is currently open for enrollment in centers in Europe and Canada and is designed to serve as a registration trial for European approval.

"We are very pleased to initiate the registration study following excellent clinical results from the phase I/II study with ATIR(TM)." says Dr. Manja Bouman, CEO of Kiadis Pharma. "ATIR(TM) has shown a low TRM at one year post transplantation and a high overall survival in a patient population with no standard treatment options left. As an orphan product addressing a high unmet need, we aim to take advantage of a fast development path for ATIR(TM)."

"As the pioneer of ATIR(TM) I am very excited about this next major development milestone, a multinational registration study" says Dr. Denis Claude Roy of the University of Montreal. "I am a strong believer that ATIR(TM) will open up a whole new treatment field for a very large patient group which currently has no treatment options left."

About ATIR(TM)

ATIR(TM), a donor lymphocyte preparation depleted of alloreactive T-cells, is under development to reduce transplant related mortality (TRM) following an allogeneic hematopoietic stem cell transplantation (HSCT). ATIR(TM) is designed to provide early immune reconstitution to fight infections and remaining tumor cells (by eliminating the use of prophylactic immune suppressants) while preventing acute severe (Grade III/IV) Graft versus Host Disease. ATIR(TM) thereby significantly improves the outcome of the transplant procedure. Moreover, it enables the use of a mismatched, related (haplo-identical) donor, thus providing virtually everyone with an immediately available donor and treatment, thereby addressing a high unmet medical need as patients eligible for an allogeneic transplantation but without a matched donor available in general have no treatment options left.

ATIR(TM) has been granted orphan drug designations from both the FDA and the EMEA.

About Kiadis Pharma

Kiadis Pharma is an oncology focused biopharmaceutical development company with cell based products in clinical development. The company develops products that offer novel treatment options for terminally ill cancer patients and address significant unmet medical needs. The key focus indication for Kiadis Pharma is limitations and complications of bone marrow transplantation procedures. Kiadis Pharma is located in Amsterdam, The Netherlands. For more information about Kiadis Pharma, please visit

English release is provided by Kiadis Pharma. Equivalent translations are from a third party.

SOURCE Kiadis Pharma

SOURCE Kiadis Pharma
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Kiadis Pharma Reports Successful End of Phase II Meeting With FDA for Reviroc
2. Kiadis Pharma Receives Orphan Drug Designation for Rhitol(TM) From the FDA
3. EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation
4. Kiadis Pharma Announces Continued Collaboration With Professor Velardi on its Lead Product ATIR(TM)
5. Kiadis Pharma Appoints Dr. Maarten Egeler, MD PhD as Chief Medical Officer
6. Kiadis Pharma Reports ATIR(TM) Clinical Data, Further Supporting its Potential in Mismatched Bone Marrow Transplantations
7. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
8. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
11. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
Post Your Comments:
(Date:10/12/2015)... 12, 2015  Rebiotix Inc. today announced that ... its lead Microbiota Restoration Therapy (MRT) RBX2660 as ... Clostridium difficile (C diff) infection, a ... 29,000 deaths in the U.S. annually. 1 ... was founded to revolutionize the treatment of debilitating ...
(Date:10/12/2015)... , Oct. 12, 2015  Patara Pharma, a ... and inflammatory diseases and conditions, today announced the ... stock financing. Concurrent with the close of its ... a Loan and Security Agreement with Silicon Valley ... $7 million. Patara will use the funds from ...
(Date:10/12/2015)... ... October 12, 2015 , ... Dr. Carl Peck, MD, ... the firm as a Premier Expert consultant. NDA Partners Premier Experts are ... value to the company's clients. Premier Experts collaborate to design and implement ...
(Date:10/10/2015)... , le 10 octobre 2015 Le 8 octobre, ... intégré dans le Registre du Congrès sa déclaration ... pour la sensibilisation autour du plasma (IPAW), qui ... sponsorisée par la Plasma Protein Therapeutics Association ... à : , Sensibiliser l,opinion publique ...
Breaking Biology Technology:
(Date:10/5/2015)... 5, 2015 ) ... NXT-ID, Inc. (NASDAQ: NXTD ), a biometric authentication ... --> ) releases the following ... NXTD ), a biometric authentication company focused on the ... Group ( ) releases the following ...
(Date:9/30/2015)... , Sept. 30, 2015  With nearly 300,000 ... number of new SCIs estimated to reach 12,500 annually, ... Southern California Resource Services for Independent Living (SCRS-IL) ... in California opening doors to ... of programs and services, notably assistive technology services and ...
(Date:9/29/2015)... , Sept. 29, 2015 ... employee productivity while also saving energy , Minimized ... as Low Power Active Mode and embedded Fujitsu PalmSecure ... Fujitsu today shows that good things ... and refreshed models to its enterprise desktop and mobile ...
Breaking Biology News(10 mins):